A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist

OBJECTIVE: To compare effects of an initial dose of calcitonin gene‐related peptide (CGRP) monoclonal antibody (mAb) antagonists on gastrointestinal (GI) motility in patients with migraine and to explore if the mechanistic difference contributes to GI adverse events (AEs). BACKGROUND: Different freq...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudrow, David, Nguyen, Linda, Semler, Jack, Stroud, Chad, Samaan, Karen, Hoban, Deirdre B., Wietecha, Linda, Hsu, Hai‐An, Pearlman, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826055/
https://www.ncbi.nlm.nih.gov/pubmed/36111429
http://dx.doi.org/10.1111/head.14390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826055/
https://www.ncbi.nlm.nih.gov/pubmed/36111429
http://dx.doi.org/10.1111/head.14390

Ejemplares similares